HomeTechConcurrent Technologies Full Year 2023 Earnings: EPS: UK£0.05 (vs UK£0.013 in FY...

Concurrent Technologies Full Year 2023 Earnings: EPS: UK£0.05 (vs UK£0.013 in FY 2022)

Date:

Related stories

Fuel Ventures secures £20m Chinese investment round, strengthening UK-China tech ties

Fuel Ventures, one of the UK’s most prominent venture...

Space tech consortium secures government funding for in-orbit sandbox

A consortium of space tech firms has been approved...

Christmas shopping chaos as ‘server goes down’ at major UK supermarket

Last-minute Christmas shoppers are facing chaos this morning as...

Amazon Workers Go On Strike Across US | Silicon UK Tech News

Amazon staff in seven cities across US go on...

How can the UK help European telecoms business in 2025?

The seven-year funding programme is designed to give companies...
spot_imgspot_img

Concurrent Technologies (LON:CNC) Full Year 2023 Results

Key Financial Results

  • Revenue: UK£31.7m (up 73% from FY 2022).
  • Net income: UK£3.87m (up 292% from FY 2022).
  • Profit margin: 12% (up from 5.4% in FY 2022). The increase in margin was driven by higher revenue.
  • EPS: UK£0.05 (up from UK£0.013 in FY 2022).
AIM:CNC Earnings and Revenue History May 3rd 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Concurrent Technologies Earnings Insights

Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Tech industry in Europe.

Performance of the market in the United Kingdom.

The company’s shares are up 8.5% from a week ago.

Risk Analysis

What about risks? Every company has them, and we’ve spotted 1 warning sign for Concurrent Technologies you should know about.

Valuation is complex, but we’re helping make it simple.

Find out whether Concurrent Technologies is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories

spot_img